Graves' Disease: Can It Be Cured?
Wilmar M. Wiersinga (Wiersinga WM)
Endocrinol Metab. 2019;34(1):29-38.   Published online 2019 Mar 21     DOI: https://doi.org/10.3803/EnM.2019.34.1.29
Citations to this article as recorded by Crossref logo
Most Patients with Graves’ Disease Treated with Antithyroid Drugs Eventually Require Additional Therapies
Mary H. Samuels
Clinical Thyroidology.2020; 32(1): 9.     CrossRef
Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study
Juan P. Brito, Stephanie Payne, Naykky Singh Ospina, Rene Rodriguez-Gutierrez, Spyridoula Maraka, Lindsey R. Sangaralingham, Nicole M. Iñiguez-Ariza, Victor M. Montori, Marius N. Stan
Thyroid.2020; 30(3): 357.     CrossRef
Long-Term Treatment of Hyperthyroidism with Antithyroid Drugs: 35 Years of Personal Clinical Experience
Fereidoun Azizi
Thyroid.2020; 30(10): 1451.     CrossRef
Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves’ disease patients
Rui-Ting Hu, De-Shan Liu, Bin Li
BMC Endocrine Disorders.2020;[Epub]     CrossRef
The Concept of Cure in Thyroid Diseases
Fereidoun Azizi
International Journal of Endocrinology and Metabolism.2020;[Epub]     CrossRef
Der Biomarker TSH bei Schilddrüsenautonomien
K. Passek, N. Zulauf, E. Wanke, G. M. Oremek
Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie.2020; 70(4): 177.     CrossRef
Management of Graves’ Hyperthyroidism: More Than a Century of Progression
Hengameh Abdi, Atieh Amouzegar
International Journal of Endocrinology and Metabolism.2020;[Epub]     CrossRef
Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism
Rosario Le Moli, Pasqualino Malandrino, Marco Russo, Fabrizio Lo Giudice, Francesco Frasca, Antonino Belfiore, Riccardo Vigneri
Frontiers in Endocrinology.2020;[Epub]     CrossRef
Prediction of Relapse After Antithyroid Drugs Withdrawal: A Narrative Review
Pei-Wen Wang
International Journal of Endocrinology and Metabolism.2020;[Epub]     CrossRef
Radioiodine-131 therapy (RIT) in benign thyroid diseases: Personalized prescription based on objectives with optional use of pharmacological modulators
J. Clerc
Médecine Nucléaire.2020; 44(4): 250.     CrossRef
PREDICTING THE RISK OF GRAVES DISEASE RELAPSE: COMMENTARY ON “THYROID PEROXIDASE ANTIBODY POSITIVITY IS ASSOCIATED WITH RELAPSE-FREE SURVIVAL FOLLOWING ANTITHYROID DRUG TREATMENT FOR GRAVES DISEASE”
D. Gallo, M. L. Tanda, E. Piantanida
Endocrine Practice.2020; 26(9): 1039.     CrossRef
Integrating Five Feature Types Extracted From Ultrasonograms to Improve the Prediction of Thyroid Papillary Carcinoma
Renxiang Zhu, Zhongyu Wang, Yifan Zhang, Bingxin Yu, Mingran Qi, Xin Feng, Chenjun Wu, Yuxuan Cui, Lan Huang, Fan Li, Fengfeng Zhou
IEEE Access.2019; 7: 101820.     CrossRef
Serum TSH Receptor Antibodies Fall Gradually and Only Rarely Switch Functional Activity in Treated Graves’ Disease
Mary H. Samuels
Clinical Thyroidology.2019; 31(8): 330.     CrossRef
Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy
Yun Mi Choi, Mi Kyung Kwak, Sang Mo Hong, Eun-Gyoung Hong
Endocrinology and Metabolism.2019; 34(3): 268.     CrossRef
A transgenic mouse that spontaneously develops pathogenic TSH receptor antibodies will facilitate study of antigen-specific immunotherapy for human Graves’ disease
Sandra M. McLachlan, Basil Rapoport
Endocrine.2019; 66(2): 137.     CrossRef